Cover image for Vol. 120 Issue 18

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 4.901

ISI Journal Citation Reports © Ranking: 2013: 38/202 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians


  1. 1 - 100
  2. 101 - 166
  1. Original Articles

    1. Disease Site

      Gynecologic Oncology
      Polymerase ɛ (POLE) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing

      Caroline C. Billingsley, David E. Cohn, David G. Mutch, Julie A. Stephens, Adrian A. Suarez and Paul J. Goodfellow

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.29046

      Mutation in the polymerase ɛ gene (POLE) exonuclease domain is a defining feature of a subgroup of endometrial cancers (ECs) with very high somatic mutation burden and for which improved progression-free survival has been reported; however, in this analysis of 544 ECs, no significant survival association is identified, indicating that POLE mutation is unlikely to be a clinically applicable prognostic marker. However, some high rates of POLE defects in a subset of microsatellite unstable cancers appear to be associated with somatic mutation in DNA mismatch repair genes, a finding with important implications for Lynch syndrome testing in patients with EC.

  2. Editorials

    1. POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: Implications for Lynch syndrome testing

      Panagiotis A. Konstantinopoulos and Ursula A. Matulonis

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.29057

      In endometrial cancer, the presence of polymerase ɛ (POLE) exonuclease domain mutations in immunohistochemically abnormal/microsatellite unstable/mutL homolog1-unmethylated tumors may serve as a marker of somatic origin. These mutations may be important in making determinations and recommendations for mismatch repair gene mutation testing in women with endometrial cancer.

  3. Original Articles

    1. Discipline

      Medical Oncology
      Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian

      Jacqueline Mersch, Michelle A. Jackson, Minjeong Park, Denise Nebgen, Susan K. Peterson, Claire Singletary, Banu K. Arun and Jennifer K. Litton

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.29041

      In a cohort of more than 1000 known mutation carriers, BRCA2 mutations are associated with a higher rate of pancreatic cancer than previously reported. Increases have also been observed in prostate cancer and melanoma.

    2. Pediatric Oncology
      Parent decision-making around the genetic testing of children for germline TP53 mutations

      Melissa A. Alderfer, Kristin Zelley, Robert B. Lindell, Ana Novokmet, Phuong L. Mai, Judy E. Garber, Deepika Nathan, Sarah Scollon, Nicolette M. Chun, Andrea F. Patenaude, James M. Ford, Sharon E. Plon, Joshua D. Schiffman, Lisa R. Diller, Sharon A. Savage, David Malkin, Carol A. Ford and Kim E. Nichols

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.29027

      Li-Fraumeni Syndrome (LFS) is a rare genetic cancer predisposition syndrome caused by germline TP53 mutations in which up to 20% of mutation carriers develop cancer during childhood. Although empirical evidence regarding benefits and risks of TP53 testing during childhood are lacking, most parents in our study decided easily in favor of testing and perceived a range of advantages that outweighed risks.

    3. Medical Oncology
      Elevated risks of subsequent primary malignancies in patients with thyroid cancer: A nationwide, population-based study in Korea

      Yoon Young Cho, Jiwon Lim, Chang-Mo Oh, Junsun Ryu, Kyu-Won Jung, Jae Hoon Chung, Young-Joo Won and Sun Wook Kim

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.29025

      In patients with primary thyroid cancer, the risks of several cancers are elevated significantly during follow-up. Thus, physicians are needed to pay special attention in their care of thyroid cancer patients and long-term survivors.

  4. Editorials

    1. Is there an increased risk of second primary malignancy after diagnosis of thyroid cancer?

      Aarti Mathur, Eric B. Schneider and Martha A. Zeiger

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.29026

      Recent reports on the risk of developing second primary malignancies have raised concern about whether enhanced surveillance is warranted in patients with thyroid cancer. An excellent review of the incidences and types of second primary malignancies in a Korean population treated for thyroid cancer is provided in this issue of Cancer.

  5. Original Articles

    1. Discipline

      Clinical Trials
      Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

      Jorge E. Cortes, Stuart L. Goldberg, Eric J. Feldman, David A. Rizzeri, Donna E. Hogge, Melissa Larson, Arnaud Pigneux, Christian Recher, Gary Schiller, Krzysztof Warzocha, Hagop Kantarjian, Arthur C. Louie and Jonathan E. Kolitz

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.28974

      CPX-351, a liposome-encapsulated fixed-molar-ratio formulation of cytarabine and daunorubicin, exploits molar ratio–dependent drug-drug synergy to enhance antileukemic efficacy. A randomized phase II study comparing CPX-351 with investigators' choice of first salvage therapy in first-relapse patients demonstrated improved response, event-free survival, and overall survival (HR, 0.55; P = .02) in the poor-risk strata.

    2. Disparities Research
      Provider-based research networks may improve early access to innovative colon cancer treatment for African Americans treated in the community

      Dolly C. Penn, YunKyung Chang, Anne-Marie Meyer, Christina DeFilippo Mack, Hanna K. Sanoff, Karyn B. Stitzenberg and William R. Carpenter

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29028

      Among older patients with stage III colon cancer, there is a differential impact of race on oxaliplatin receipt depending on clinical practice affiliation. Provider-based research networks may facilitate early access to innovative treatment for African American patients with stage III colon cancer.

    3. Pediatric Oncology
      Pleuropulmonary blastoma: A report on 350 central pathology–confirmed pleuropulmonary blastoma cases by the International Pleuropulmonary Blastoma Registry

      Yoav H. Messinger, Douglas R. Stewart, John R. Priest, Gretchen M. Williams, Anne K. Harris, Kris Ann P. Schultz, Jiandong Yang, Leslie Doros, Philip S. Rosenberg, D. Ashley Hill and Louis P. Dehner

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29032

      Three hundred fifty centrally reviewed pleuropulmonary blastoma cases confirm that the outcomes of type I are better than the outcomes of type II and that the outcomes of type II are better than the outcomes of type III. Thus, the early detection of type I pleuropulmonary blastoma before its progression to type II or III may improve outcomes.

    4. Disease Site

      Gynecologic Oncology
      Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for personalization of therapy in ovarian cancer

      Shujuan Liu, Yong Zheng, Davide Volpi, Muna El-Kasti, Daniel Klotz, Iain Tullis, Andrea Henricks, Leticia Campo, Kevin Myers, Alex Laios, Peter Thomas, Tony Ng, Sunanda Dhar, Christian Becker, Borivoj Vojnovic and Ahmed Ashour Ahmed

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29029

      Biomarker-based selection for targeted therapy has been a key criterion for the successful application of targeted therapies. This work demonstrates the utility of an in-house developed optical imaging system for detecting the expression of the c-Met oncogene in submillimeter ovarian cancer deposits.

    5. Endocrine Disease
      Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay

      Yuri E. Nikiforov, Sally E. Carty, Simon I. Chiosea, Christopher Coyne, Umamaheswar Duvvuri, Robert L. Ferris, William E. Gooding, Steven P. Hodak, Shane O. LeBeau, N. Paul Ohori, Raja R. Seethala, Mitchell E. Tublin, Linwah Yip and Marina N. Nikiforova

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29038

      The diagnostic performance of the most complete next-generation sequencing panel of thyroid cancer genetic markers is evaluated in nodules with follicular neoplasm/suspicious for follicular neoplasm cytology. The results indicate that this panel provides highly accurate cancer detection in such nodules and should facilitate the optimal management of these patients.

    6. Discipline

      Supportive Care
      Cancer caregiving predicts physical impairments: Roles of earlier caregiving stress and being a spousal caregiver

      Youngmee Kim, Charles S. Carver, Kelly M. Shaffer, Ted Gansler and Rachel S. Cannady

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29040

      Stressed caregivers are more likely to develop heart disease and spousal caregivers are more likely than other caregivers to develop arthritis and chronic back pain years after the initial caregiving experience. The current results provide the first evidence that subjective caregiving stress and spousal role independently have aggravating effects on caregivers' physical health.

    7. Psychosocial Oncology
      Patterns of psychiatric medication use among nationally representative long-term cancer survivors and controls

      Ilana M. Braun, Sowmya R. Rao, Fremonta L. Meyer and Giuseppe Fedele

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29014

      Long-term cancer survivors and cancer-naive controls demonstrate comparable rates of psychiatric prescription medication use. These findings contribute to an emerging hypothesis that, in general, long-term cancer survivors are not a particularly psychiatrically vulnerable group.

    8. Disease Site

      Head and Neck Disease
      Human papillomavirus 16 oncoprotein regulates the translocation of β-catenin via the activation of epidermal growth factor receptor

      Zhongliang Hu, Susan Müller, Guoqing Qian, Jing Xu, Sungjin Kim, Zhengjia Chen, Ning Jiang, Dongsheng Wang, Hongzheng Zhang, Nabil F. Saba, Dong M. Shin and Zhuo Georgia Chen

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29039

      Human papillomavirus 16 E6 mediates the translocation of β-catenin to the nucleus, which may be regulated by activated epidermal growth factor receptor.

  6. Editorials

    1. Medication use as a surrogate marker of emotional health in long-term cancer survivors

      Stewart B. Fleishman

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29013

      Evaluation of the pattern of psychiatric medications used by long-term cancer survivors is an inadequate surrogate marker with which to gauge survivors' emotional health. Specialty-level assessment and treatment are important for precise differential diagnosis and treatment when central nervous system disease recurrence can mimic psychiatric symptoms.

  7. Correspondence

    1. Reply to sarcopenia is more than simply documenting low skeletal muscle mass

      Matthew K. Tollefson and Sarah P. Psutka

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29017

    2. Sarcopenia is more than simply documenting low skeletal muscle mass

      Umit Cintosun, Ilker Tasci, Vildan Binay Safer and Umut Safer

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29016

  8. Original Articles

    1. Discipline

      Symptom Control and Palliative Care
      Dyadic psychosocial intervention for advanced lung cancer patients and their family caregivers: Results of a randomized pilot trial

      Hoda Badr, Cardinale B. Smith, Nathan E. Goldstein, Jorge E. Gomez and William H. Redd

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29009

      Advanced lung cancer patients and their caregivers who receive an intervention show significant improvements in depression, anxiety, and caregiver burden in comparison with those receiving usual medical care. Large effect sizes (d > 1.2) are also shown for patient and caregiver competence and relatedness and caregiver autonomous motivation for providing care.

    2. Disparities Research
      Attitudes toward molecular testing for personalized cancer therapy

      Rafeek A. Yusuf, Deevakar Rogith, Shelly R. A. Hovick, Susan K. Peterson, Allison M. Burton-Chase, Bryan M. Fellman, Yisheng Li, Carolyn McKinney, Elmer V. Bernstam and Funda Meric-Bernstam

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.28966

      The authors assess the attitudes of 100 breast cancer patients regarding molecular testing for personalized therapy and research with a questionnaire. Most patients are willing to undergo molecular testing and minimally invasive procedures to guide approved or experimental therapy, but there are significant differences in attitudes toward molecular testing between racial groups.

  9. Correspondence

    1. Reply to Charlson score and competing mortality

      Timothy J. Daskivich, Mark S. Litwin and Christopher Saigal

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.28955

    2. Charlson score and competing mortality

      Michael Froehner, Rainer Koch and Manfred P. Wirth

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.28958

  10. Erratum

    1. You have free access to this content
    2. You have free access to this content
  11. Original Articles

    1. Discipline

      Complementary Medicine
      Randomized, placebo-controlled trial of K1 acupoint acustimulation to prevent cisplatin-induced or oxaliplatin-induced nausea

      Yehua Shen, Luming Liu, Joseph S. Chiang, Zhiqiang Meng, M. Kay Garcia, Zhen Chen, Huiting Peng, Wenying Bei, Qi Zhao, Amy R. Spelman and Lorenzo Cohen

      Article first published online: 9 SEP 2014 | DOI: 10.1002/cncr.28973

      This randomized, placebo-controlled trial investigated whether electrostimulation of acupoint K1 could control chemotherapy-induced nausea and vomiting among patients with primary or metastatic liver cancer. Electrostimulation of acupoint K1 did not appear to result in the prevention of acute or delayed cisplatin-induced or oxaliplatin-induced nausea or vomiting when combined with antiemetics.

    2. Disease Site

      Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma

      Yi-Bin Chen, Tracy Batchelor, Shuli Li, Ephraim Hochberg, Mark Brezina, Sooae Jones, Candice Del Rio, Morgan Curtis, Karen K. Ballen, Jeffrey Barnes, Andrew S. Chi, Jorg Dietrich, Jessica Driscoll, Elizabeth R. Gertsner, Fred Hochberg, Ann S. LaCasce, Steven L. McAfee, Thomas R. Spitzer, Lakshmi Nayak and Philippe Armand

      Article first published online: 9 SEP 2014 | DOI: 10.1002/cncr.29023

      Using high-dose systemic rituximab may allow higher concentrations to penetrate the central nervous system. This article presents a phase 2 trial combining high-dose rituximab with standard autologous stem cell transplantation and shows compelling results in patients with central nervous system involvement by non-Hodgkin lymphoma.

  12. Review Articles

    1. Multimodal imaging for improved diagnosis and treatment of cancers

      Clare M. C. Tempany, Jagadeesan Jayender, Tina Kapur, Raphael Bueno, Alexandra Golby, Nathalie Agar and Ferenc A. Jolesz

      Article first published online: 9 SEP 2014 | DOI: 10.1002/cncr.29012

      Multimodal molecular imaging enables the detection, characterization, diagnosis, and treatment of cancer. Used in real time during therapy, it allows more complete cancer therapy with minimal collateral damage to healthy surrounding tissue. Image-guided therapy using advanced multimodality imaging for brain, prostate, and lung cancers is reviewed.

  13. Original Articles

    1. Discipline

      Symptom Control and Palliative Care
      Dying in cancer centers: Do the circumstances allow for a dignified death?

      Karin Jors, Sandra Adami, Carola Xander, Cornelia Meffert, Jan Gaertner, Hubert Bardenheuer, Dieter Buchheidt, Regine Mayer-Steinacker, Marén Viehrig, Wolfang George and Gerhild Becker

      Article first published online: 8 SEP 2014 | DOI: 10.1002/cncr.28702

      Cancer centers today are providing dying patients with a more dignified experience than in the past. Among physicians and nurses working at cancer centers in Germany, 56% believe that patients are able to die in dignity on their ward.

    2. Epidemiology
      Physician-reported barriers to referring cancer patients to specialists: Prevalence, factors, and association with career satisfaction

      Daniel H. Kwon, Diana M. Tisnado, Nancy L. Keating, Carrie N. Klabunde, John L. Adams, Afshin Rastegar, Mark C. Hornbrook and Katherine L. Kahn

      Article first published online: 5 SEP 2014 | DOI: 10.1002/cncr.29019

      Many physicians experience barriers to specialty referral for cancer patients. Physicians in large, highly managed care practices report fewer barriers, and high reporting of barriers is associated with low career satisfaction.

    3. Disease Site

      Clinico-morphological features of BRAF inhibition–induced proliferative skin lesions in cancer patients

      Viswanath Reddy Belum, Alyx C. Rosen, Natalia Jaimes, George Dranitsaris, Melissa P. Pulitzer, Klaus J. Busam, Ashfaq A. Marghoob, Richard D. Carvajal, Paul B. Chapman and Mario E. Lacouture

      Article first published online: 3 SEP 2014 | DOI: 10.1002/cncr.28980

      Despite improved cancer outcomes with BRAF inhibitors, the characterization and management of the associated adverse events exemplify the challenges of survivorship care. Published studies involving BRAF inhibitors reflect an adverse event profile that is characterized by proliferative skin lesions (keratoacanthomas/cutaneous squamous cell carcinomas and verrucous lesions), maculopapular rashes, and hyperkeratosis. With regulatory approval and expanding use of vemurafenib and dabrafenib, oncologists will encounter proliferative skin lesions more often. Recognition of their key identifying features and appropriate management are crucial for ensuring consistent dosing of life-saving anticancer therapy, maintenance of health-related quality of life, and lower morbidity associated with adverse event management.

    4. Genitourinary Disease
      Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma

      Ahmed Q. Haddad, Payal Kapur, Nirmish Singla, Jay D. Raman, Matthew T. Then, Philipp Nuhn, Alexander Buchner, Patrick Bastian, Christian Seitz, Shahrokh F. Shariat, Karim Bensalah, Nathalie Rioux-Leclercq, Arthur Sagalowsky, Yair Lotan and Vitaly Margulis

      Article first published online: 3 SEP 2014 | DOI: 10.1002/cncr.28976

      Alteration of mammalian target of rapamycin biomarkers predicts survival outcomes in patients with clear cell renal carcinoma. This marker panel has prognostic value in addition to standard clinical and pathologic predictors of outcome.

    5. Breast Disease
      Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel

      Nadine Tung, Chiara Battelli, Brian Allen, Rajesh Kaldate, Satish Bhatnagar, Karla Bowles, Kirsten Timms, Judy E. Garber, Christina Herold, Leif Ellisen, Jill Krejdovsky, Kim DeLeonardis, Kristin Sedgwick, Kathleen Soltis, Benjamin Roa, Richard J. Wenstrup and Anne-Renee Hartman

      Article first published online: 3 SEP 2014 | DOI: 10.1002/cncr.29010

      Using a next-generation sequencing 25-gene panel, the frequency of mutations for patients with breast cancer in genes other than BRCA1/2 is 4.3%, and most of the mutations (3.9%) are in genes associated with breast/ovarian cancer. Approximately half of patients with mutations in genes other than BRCA1/2 are identified in moderate-penetrance genes for which the efficacy of medical management is less well defined.

    6. Hepatobiliary Disease
      KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases

      Nancy E. Kemeny, Joanne F. Chou, Marinela Capanu, Alexandra N. Gewirtz, Andrea Cercek, T. Peter Kingham, William R. Jarnagin, Yuman C. Fong, Ronald P. DeMatteo, Peter J. Allen, Jinru Shia, Celina Ang, Efsevia Vakiani and Michael I. D'Angelica

      Article first published online: 25 AUG 2014 | DOI: 10.1002/cncr.28954

      Among patients with resected colorectal liver metastases treated with adjuvant therapy, those with mutated KRAS appear to have significantly higher incidences of bone, brain, and lung metastases compared with patients with wild-type KRAS. In addition, KRAS-mutated patients had a worse recurrence-free survival (median, 26.4 months vs 14.5 months for patients with KRAS wild-type; In addition, KRAS-mutated patients had a worse recurrence-free survival (median, 14.5 months) versus median 26.4 months for patients with KRAS wild-type.

  14. Commentary

    1. The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria

      Ryan D. Gentzler, Sarah E. Yentz, Melissa L. Johnson, Alfred W. Rademaker and Jyoti D. Patel

      Article first published online: 25 AUG 2014 | DOI: 10.1002/cncr.28956

      ASCO abstracts for NSCLC trials over the last 11 years have shown an increasing rate of positive PFS and OS outcomes. Molecular biomarker and histology selection criteria in trials may account for this increase in positive outcomes.

  15. Original Articles

    1. Disease Site

      Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients

      Nathaniel H. Fleming, Judy Zhong, Inês Pires da Silva, Eleazar Vega-Saenz de Miera, Bobbi Brady, Sung Won Han, Doug Hanniford, Jinhua Wang, Richard L. Shapiro, Eva Hernando and Iman Osman

      Article first published online: 25 AUG 2014 | DOI: 10.1002/cncr.28981

      Serum-based miRNAs have prognostic clinical utility in melanoma patients for the prediction and monitoring of recurrence. Key serum miRNAs are predicted to play biological roles in melanoma disease by bioinformatics analysis.

  16. Editorial

    1. You have full text access to this OnlineOpen article
      KRAS mutation in patients undergoing hepatic resection for colorectal liver metastasis: A biomarker of cancer biology or a byproduct of patient selection?

      Kjetil Søreide, Oddvar M. Sandvik and Jon A. Søreide

      Article first published online: 25 AUG 2014 | DOI: 10.1002/cncr.28979

      Patients with colorectal cancer have experienced remarkable progress in a range of surgical and oncologic management strategies over the past few years, with a corresponding improvement in survival. The KRAS mutation may be a biomarker of cancer biology and prognosis, but also reflects patient selection.

  17. Original Articles

    1. Discipline

      Clinical Trials
      Cancer survivors' uptake and adherence in diet and exercise intervention trials: An integrative data analysis

      Rebecca N. Adams, Catherine E. Mosher, Cindy K. Blair, Denise C. Snyder, Richard Sloane and Wendy Demark-Wahnefried

      Article first published online: 25 AUG 2014 | DOI: 10.1002/cncr.28978

      Cancer survivors' demographic and medical characteristics predict their interest and participation in diet and exercise intervention trials. The findings reported here can help to guide trial procedures to enhance patient diversity and representation and assist with the interpretation of generalizability.

    2. Epidemiology
      You have full text access to this OnlineOpen article
      Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010

      Haley R. Gittleman, Quinn T. Ostrom, Chaturia D. Rouse, Jacqueline A. Dowling, Peter M. de Blank, Carol A. Kruchko, J. Bradley Elder, Steven S. Rosenfeld, Warren R. Selman, Andrew E. Sloan and Jill S. Barnholtz-Sloan

      Article first published online: 25 AUG 2014 | DOI: 10.1002/cncr.29015

      Time trends in cancer incidence rates are important to measure the changing burden of cancer on a population over time. In adults, there were significant decreases noted in the incidence of colon, breast, lung, prostate, and malignant central nervous system tumors (CNST), but a significant increase in nonmalignant CNST. There were significant increases observed in malignant CNST and nonmalignant CNST among adolescents and significant increases in acute lymphocytic leukemia, non-Hodgkin lymphoma, and malignant CNST noted in children.

    3. Disparities Research
      Impact of state-specific Medicaid reimbursement and eligibility policies on receipt of cancer screening

      Michael T. Halpern, Melissa A. Romaire, Susan G. Haber, Florence K. Tangka, Susan A. Sabatino and David H. Howard

      Article first published online: 25 AUG 2014 | DOI: 10.1002/cncr.28704

      Increased Medicaid reimbursement for physician office visits and less restrictive financial asset policies were associated with a greater likelihood of receiving cancer screening tests among Medicaid beneficiaries. Revisions to state-specific Medicaid reimbursements and eligibility policies may improve rates of appropriate cancer screening among this underserved population.

  18. Erratum

    1. You have free access to this content
  19. Original Articles

    1. Discipline

      Clinical Trials
      Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer

      Mehmet Asim Bilen, Marcella M. Johnson, Paul Mathew, Lance C. Pagliaro, John C. Araujo, Ana Aparicio, Paul G. Corn, Nizar M. Tannir, Franklin C. Wong, Michael J. Fisch, Christopher J. Logothetis and Shi-Ming Tu

      Article first published online: 22 AUG 2014 | DOI: 10.1002/cncr.28971

      To the authors' knowledge, this is the first study that combines androgen-deprivation therapy with a radiopharmaceutical agent for the treatment of patients with advanced castrate-sensitive prostate cancer. Although an improvement in progression-free survival has not been detected, the results suggest a favorable outcome for those patients with a greater tumor burden in the bone.

  20. Editorials

    1. Are patient preferences for end-of-life care socially influenced? Examining racial disparities in advance care planning

      Fay J. Hlubocky

      Article first published online: 21 AUG 2014 | DOI: 10.1002/cncr.28969

      Future research should continue empirical investigations into the social influences and additional factors responsible for the modification of preferences among racially/ethnically diverse patients with terminal cancer, because these factors would be informative for the development of a culturally sensitive, patient-centered advance planning intervention for such patients. Advance care planning interventions have the potential to significantly challenge current clinical and research practice paradigms pertaining to the provision of end-of-life care to terminal cancer patients, with particular relevance to racial and ethnic minorities who are disproportionately more likely to receive aggressive life-sustaining care.

  21. Original Articles

    1. Discipline

      Disparities Research
      End-of-life treatment preferences: A key to reducing ethnic/racial disparities in advance care planning?

      Melissa M. Garrido, Shannon T. Harrington and Holly G. Prigerson

      Article first published online: 21 AUG 2014 | DOI: 10.1002/cncr.28970

      Patient interview data are used to demonstrate that, although patient preferences against life-prolonging care differ dramatically by race/ethnicity, they are uniformly significantly associated with do-not-resuscitate order completion rates across racial/ethnic groups of patients with advanced cancer.

    2. Quality of Life
      You have full text access to this OnlineOpen article
      Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life

      Christopher R. Spencer, Hiram A. Gay, Bruce H. Haughey, Brian Nussenbaum, Douglas R. Adkins, Tanya M. Wildes, Todd A. DeWees, James S. Lewis Jr. and Wade L. Thorstad

      Article first published online: 20 AUG 2014 | DOI: 10.1002/cncr.28938

      Eliminating radiation therapy to the contralateral retropharyngeal lymph nodes and contralateral high level II lymph nodes in the clinically uninvolved neck does not increase the risk of recurrence in these areas. Limiting radiation treatment volume, as such, translates into improved patient-reported quality of life.

    3. Disease Site

      Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma

      Jaime Gállego Pérez-Larraya, Sophie Paris, Ahmed Idbaih, Caroline Dehais, Florence Laigle-Donadey, Soledad Navarro, Laurent Capelle, Karima Mokhtari, Yannick Marie, Marc Sanson, Khê Hoang-Xuan, Jean-Yves Delattre and Alain Mallet

      Article first published online: 19 AUG 2014 | DOI: 10.1002/cncr.28949

      A combined profile of preoperative insulin-like growth factor-binding protein 2 (IGFBP-2), glial fibrillary acidic protein (GFAP), and chitinase-3-like protein 1 (YKL-40) plasma levels could serve as a potential diagnostic tool for patients with glioblastoma multiforme (GBM). IGFBP-2 levels appear to constitute an independent prognostic factor in patients with GBM.

  22. Correspondence

  23. Editorials

    1. Colorectal cancer screening in the American Indian/Alaska Native population: Progress and at least one new challenge

      Patrick M. Lynch

      Article first published online: 13 AUG 2014 | DOI: 10.1002/cncr.28848

      A new report in this issue describes improvements in colorectal cancer screening among American Indians and Alaska Natives but with rates that still lag far behind those of whites and African Americans. The Affordable Care Act has provisions specifically targeting the American Indian/Alaska Native population that may or may not be positive disrupting factors in screening trends, with modality-specific and overall colorectal cancer screening patterns serving as interesting benchmarks against which to measure the impact of the Affordable Care Act the over next 10 or more years.

  24. Original Articles

    1. Discipline

      Disparities Research
      United States colorectal cancer screening practices among American Indians/Alaska Natives, blacks, and non-Hispanic whites in the new millennium (2001 to 2010)

      Michelle Dawn Johnson-Jennings, Wassim Tarraf, Kyle Xavier Hill and Hector M. González

      Article first published online: 13 AUG 2014 | DOI: 10.1002/cncr.28855

      Between the years 2001 and 2010, American Indians/Alaska Natives reported the lowest colorectal cancer screening rates compared with blacks and whites in the United States. The current findings indicate that, although considerable progress has been made to increase colorectal cancer screening for blacks and whites, progress for American Indians/Alaska Natives lagged far behind in the first decade of the 21st century. See also pages

    2. Disease Site

      Hematologic Malignancies
      IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma

      Eileen M. Boyle, Guillemette Fouquet, Stéphanie Guidez, Sarah Bonnet, Helene Demarquette, Remy Dulery, Charles Herbaux, Marie Pierre Noel, Salomon Manier, Suzanna Schraen, Brigitte Onraed, Jean-Luc Faucompré, Bernadette Hennache, Marie Odile Petillon, Claire Mathiot, Herve Avet-Loiseau, Thierry Facon, Stephen J. Harding, Philippe Moreau and Xavier Leleu

      Article first published online: 12 AUG 2014 | DOI: 10.1002/cncr.28946

      The immunoglobulin (Ig) A Hevylite test is a new tool that may be used to adequately monitor patients with IgA multiple myeloma. By measuring isotype paired suppression, it offers additional prognostic information for the management of patients with IgA multiple myeloma.

    3. Discipline

      Pediatric Oncology
      Secondary malignant neoplasms among children, adolescents, and young adults with osteosarcoma

      Jean S. Lee, Steven G. DuBois, W. John Boscardin, Rosanna L. Wustrack and Robert E. Goldsby

      Article first published online: 12 AUG 2014 | DOI: 10.1002/cncr.28936

      As patients with osteosarcoma become long-term survivors, increasing attention has turned to the burden of late effects. Survivors of osteosarcoma are at an increased risk of secondary malignant neoplasms compared with the baseline population, with an increased risk noted among patients treated in the more recent era.

    4. Disease Site

      Hematologic Malignancies
      Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols

      Cristina Motlló, Josep-María Ribera, Mireia Morgades, Isabel Granada, Pau Montesinos, José González-Campos, Pascual Fernández-Abellán, Mar Tormo, Concepción Bethencourt, Salut Brunet, Jesús-María Hernández-Rivas, María-José Moreno, Josep Sarrà, Eloy del Potro, Pere Barba, Teresa Bernal, Carlos Grande, Javier Grau, José Cervera, Evarist Feliu and PETHEMA Group, Spanish Society of Hematology

      Article first published online: 12 AUG 2014 | DOI: 10.1002/cncr.28950

      After reviewing the karyotypes of 881 adult ALL patients treated according to the protocols of the PETHEMA Group between 1993 and 2012, the complex karyotype and the monosomal karyotype did no confer worse prognosis.

    5. Genitourinary Disease
      Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients

      Lisa Derosa, Luca Galli, Paola Orlandi, Anna Fioravanti, Teresa Di Desidero, Andrea Fontana, Andrea Antonuzzo, Elisa Biasco, Azzurra Farnesi, Riccardo Marconcini, Giulio Francia, Romano Danesi, Alfredo Falcone and Guido Bocci

      Article first published online: 8 AUG 2014 | DOI: 10.1002/cncr.28953

      The present multicenter, prospective, non-randomized phase II clinical study demonstrates that the combination of docetaxel and prednisone plus metronomic cyclophosphamide and celecoxib is effective as a first-line treatment in patients with mCRPC, and that it shows favorable toxicity. Moreover, the investigation of -1154A/G VEGF polymorphism, and of VEGF and bFGF plasma levels after the first cycle of chemotherapy suggests that these pharmacodynamic indices may be useful markers to predict a better outcome.

    6. Chest and Lung Disease
      Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib

      Boe S. Sorensen, Lin Wu, Wen Wei, Julie Tsai, Britta Weber, Ebba Nexo and Peter Meldgaard

      Article first published online: 7 AUG 2014 | DOI: 10.1002/cncr.28964

      Using a new method that allows for the quantification of the level of tumor DNA with epidermal growth factor receptor (EGFR) mutations in a blood sample, the authors were able to monitor the effect of the EGFR-targeting agent erlotinib in patients with lung cancer. Most interestingly, the results of the current study demonstrate that a mutation (T790M) causing erlotinib resistance can be detected in the blood up to 1 year earlier than disease progression can be identified by Response Evaluation Criteria In Solid Tumors (RECIST) criteria.

  25. Editorials

    1. Monitoring cancer through the blood

      Cloud P. Paweletz and Pasi A. Jänne

      Article first published online: 7 AUG 2014 | DOI: 10.1002/cncr.28967

      Tumor biopsies remain the gold standard for the evaluation of genetic changes in tumors either at diagnosis or after treatment with targeted therapies. However, this is not always feasible and can seldom be performed more than once. Noninvasive techniques that measure the allelic burden in blood have the potential to realize genotype-directed cancer therapy. These technologies can potentially be used for noninvasive tumor genotyping and also provide an opportunity for disease monitoring. Several non-invasive genotyping technologies are currently under development and being evaluated in patients treated with targeted therapies.

  26. Correspondence

    1. In-bag morcellation for presumed myoma retrieval at laparoscopy

      Giorgio Bogani, Maurizio Serati, Stefano Uccella and Fabio Ghezzi

      Article first published online: 7 AUG 2014 | DOI: 10.1002/cncr.28959

  27. Original Articles

    1. Discipline

      Outcomes Research
      Health-related quality of life as a prognostic factor in patients with advanced cancer

      Jennifer L. Steel, David A. Geller, Tiana L. Robinson, Alexandra Y. Savkova, Deborah S. Brower, J. Wallis Marsh and Allan Tsung

      Article first published online: 7 AUG 2014 | DOI: 10.1002/cncr.28902

      Health-related quality of life was found to be prognostic of survival in patients with hepatocellular and cholangiocarcinoma while controlling for demographics, disease-specific factors, and treatment-related factors.

    2. Disease Site

      Head and Neck Disease
      Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck

      Nabil F. Saba, Selwyn J. Hurwitz, Kelly Magliocca, Sungjin Kim, Taofeek K. Owonikoko, Donald Harvey, Suresh S. Ramalingam, Zhengjia Chen, Jackie Rogerio, Jennifer Mendel, Scott A. Kono, Colleen Lewis, Amy Y. Chen, Kristin Higgins, Mark El-Deiry, Trad Wadsworth, Jonathan J. Beitler, Dong M. Shin, Shi-Yong Sun and Fadlo R. Khuri

      Article first published online: 7 AUG 2014 | DOI: 10.1002/cncr.28965

      This article describes clinical, pharmacokinetic, and tissue biomarker correlative studies in a phase 1 trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck combining for the first time a platinum (carboplatin) with cetuximab and everolimus. The combination of 2 biomarkers, the p-p44/42 weighted index and the phosphorylated mammalian target of rapamycin weighted index, has a high predictive discrimination power for a clinical response (areas under the curve of 0.9583 and 0.9167, respectively). A 2-compartment mixed-effects pharmacokinetic model is consistent with previously described studies. The maximum tolerated dose of everolimus in this combination is 2.5 mg every other day. Despite the observed toxicities, this combination is associated with an encouraging response rate and progression-free survival and may deserve further investigation in a better selected population.

    3. Discipline

      Agent Orange exposure and cancer incidence in Korean Vietnam veterans: A prospective cohort study

      Sang-Wook Yi and Heechoul Ohrr

      Article first published online: 7 AUG 2014 | DOI: 10.1002/cncr.28961

      Low levels of exposure to Agent Orange (2,3,7,8-tetrachlorodibenzo-p-dioxin) decades earlier may increase an individual's overall cancer risk. Exposure to Agent Orange may increase the risk of cancers of the mouth, salivary glands, stomach, and liver.

  28. Editorials

    1. Challenges in investigating the association between Agent Orange and cancer: Site-specific cancer risk and accuracy of exposure assessment

      Thomas H. Sinks

      Article first published online: 7 AUG 2014 | DOI: 10.1002/cncr.28962

      The findings of the study by Yi and Ohrr in the current issue of Cancer add to our overall understanding of the health risks from exposures to Agent Orange. Large numbers of individuals were potentially exposed to Agent Orange during the Vietnam War and this report reminds us of the critical importance of accurate exposure assessment and the desire for epidemiologic studies to provide scientific clarity, even in the most difficult of circumstances.

  29. Correspondence

    1. Poverty and lung cancer incidence

      Steven Lehrer, Sheryl Green and Kenneth E. Rosenzweig

      Article first published online: 5 AUG 2014 | DOI: 10.1002/cncr.28960

  30. Review Articles

    1. Novel endoscopic diagnosis for bladder cancer

      Seth P. Lerner and Alvin Goh

      Article first published online: 5 AUG 2014 | DOI: 10.1002/cncr.28905

  31. Original Articles

    1. Disease Site

      Gastrointestinal Disease
      Evaluation of a 4-protein serum biomarker panel—biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)—for the detection of esophageal adenocarcinoma

      Ali H. Zaidi, Vanathi Gopalakrishnan, Pashtoon M. Kasi, Xuemei Zeng, Usha Malhotra, Jeya Balasubramanian, Shyam Visweswaran, Mai Sun, Melanie S. Flint, Jon M. Davison, Brian L. Hood, Thomas P. Conrads, Jacques J. Bergman, William L. Bigbee and Blair A. Jobe

      Article first published online: 5 AUG 2014 | DOI: 10.1002/cncr.28963

      A vertically integrated, proteomics-based biomarker discovery approach has been used successfully to develop and validate a 4-protein serum biomarker panel (biglycan, myeloperoxidase, annexin-A6, and protein S100-A9 [B-AMP]) for esophageal adenocarcinoma. Because of its ease of serum sample collection and analysis at relatively low cost, B-AMP holds significant promise for early, noninvasive detection and monitoring of esophageal adenocarcinoma.

    2. You have full text access to this OnlineOpen article
      A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma

      Heath D. Skinner, Jeffrey H. Lee, Manoop S. Bhutani, Brian Weston, Wayne Hofstetter, Ritsuko Komaki, Hironori Shiozaki, Roopma Wadhwa, Kazuki Sudo, Elena Elimova, Shumei Song, Yuanqing Ye, Maosheng Huang, Jaffer Ajani and Xifeng Wu

      Article first published online: 4 AUG 2014 | DOI: 10.1002/cncr.28911

      The current article describes a validated tumor miRNA expression profile consisting of 4 miRNAs that is highly predictive of response to chemoradiation in esophageal adenocarcinoma. Use of this panel could lead to the individualization of treatment in this disease.

  32. Review Articles

    1. Cytotoxic and DNA-targeted therapy in urothelial cancer: Have we squeezed the lemon enough?

      Arjun V. Balar and Matthew I. Milowsky

      Article first published online: 4 AUG 2014 | DOI: 10.1002/cncr.28754

      Clinical trials of cytotoxic chemotherapy in patients with urothelial cancer have reached a plateau in clinical benefit. The focus of the urothelial cancer research community should now be directed toward the identification of novel targets using modern technologies such as next-generation sequencing with the ultimate goal of developing predictive biomarkers for patients who may benefit from cytotoxic chemotherapy, targeted therapy, or both.

  33. Original Articles

    1. Disease Site

      Gynecologic Oncology
      Patient preferences in advanced or recurrent ovarian cancer

      Laura J. Havrilesky, Angeles Alvarez Secord, Jessie A. Ehrisman, Andrew Berchuck, Fidel A. Valea, Paula S. Lee, Stephanie L. Gaillard, Greg P. Samsa, David Cella, Kevin P. Weinfurt, Amy P. Abernethy and Shelby D. Reed

      Article first published online: 4 AUG 2014 | DOI: 10.1002/cncr.28940

      In this study of women with ovarian cancer, progression-free survival is the predominant driver of patient preferences for chemotherapy regimens. However, these women are willing to trade significant progression-free survival time for reductions in treatment-related toxicity.

    2. Soft Tissue and Bone Sarcoma
      Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy

      John T. Mullen, Francis J. Hornicek, David C. Harmon, Kevin A. Raskin, Yen-Lin Chen, Jackie Szymonifka, Beow Y. Yeap, Edwin Choy, Thomas F. DeLaney and G. Petur Nielsen

      Article first published online: 31 JUL 2014 | DOI: 10.1002/cncr.28945

      Although histologic response to chemotherapy has been shown to be an independent prognostic factor in patients with osteosarcoma and Ewing sarcoma, its prognostic impact among patients with soft tissue sarcoma is less clear. In a homogeneous population of patients with high-grade extremity and truncal soft tissue sarcoma who were treated with neoadjuvant chemoradiotherapy, the extent of pathologic tumor necrosis did not appear to correlate with outcome.

    3. Discipline

      Outcomes Research
      Impact of sex on the survival of patients with hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results analysis

      Dongyun Yang, Diana L. Hanna, Josh Usher, Jordan LoCoco, Pritesh Chaudhari, Heinz-Josef Lenz, V. Wendy Setiawan and Anthony El-Khoueiry

      Article first published online: 31 JUL 2014 | DOI: 10.1002/cncr.28912

      Men and women diagnosed with hepatocellular carcinoma have significantly different overall survival rates after adjusting for tumor-related and treatment-related variables. These survival differences are age-dependent and potentially related to hormonal influences on tumor biology.

    4. Disease Site

      Gynecologic Oncology
      Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing

      Sarah E. Ferguson, Melyssa Aronson, Aaron Pollett, Lua R. Eiriksson, Amit M. Oza, Steven Gallinger, Jordan Lerner-Ellis, Zahra Alvandi, Marcus Q. Bernardini, Helen J. MacKay, Golnessa Mojtahedi, Alicia A. Tone, Christine Massey and Blaise A. Clarke

      Article first published online: 31 JUL 2014 | DOI: 10.1002/cncr.28933

      In the current study, Lynch syndrome was identified in 6% of unselected women with endometrial cancer. Universal immunohistochemistry among patients aged <60 years was found to be the best screening strategy.

    5. Discipline

      Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients

      Hui-Chun Irene Su, Carolyn Haunschild, Karine Chung, Sara Komrokian, Sarah Boles, Mary Dupuis Sammel and Angela DeMichele

      Article first published online: 31 JUL 2014 | DOI: 10.1002/cncr.28942

      A novel prognostic score incorporating antimullerian hormone, age, and body size is capable of estimating the time to ovarian recovery after chemotherapy in young women with breast cancer. Pending validation, these data support using prechemotherapy ovarian reserve measures, particularly antimullerian hormone, to prospectively counsel young patients on future ovarian function.

    6. Disparities Research
      Survival analysis of Hispanics in a cohort of patients with hepatocellular carcinoma

      Santiago Aparo, Sanjay Goel, Daniel Lin, Nitin Ohri, Jonathan M. Schwartz, Yungtai Lo and Andreas Kaubisch

      Article first published online: 31 JUL 2014 | DOI: 10.1002/cncr.28867

      Hispanics with hepatocellular carcinoma experience a similar outcome of overall survival when compared with non-Hispanic whites and non-Hispanic Blacks.

    7. Pediatric Oncology
      Reirradiation of recurrent medulloblastoma: Does clinical benefit outweigh risk for toxicity?

      Cynthia Wetmore, Danielle Herington, Tong Lin, Arzu Onar-Thomas, Amar Gajjar and Thomas E. Merchant

      Article first published online: 30 JUL 2014 | DOI: 10.1002/cncr.28907

      Patients with recurrent medulloblastoma (MB) have a dismal prognosis and no standard curative therapy. The use of radiotherapy as a component of salvage therapy for relapsed MB may prolong survival of both standard and high-risk patients.

    8. Supportive Care
      Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: A randomized trial

      Jun J. Mao, John T. Farrar, Deborah Bruner, Jarcy Zee, Marjorie Bowman, Christina Seluzicki, Angela DeMichele and Sharon X. Xie

      Article first published online: 30 JUL 2014 | DOI: 10.1002/cncr.28917

      In this randomized controlled trial among breast cancer patients who experience arthralgia related to aromatase, electroacupuncture produces significant improvements in fatigue, anxiety, and depression, whereas sham acupuncture improves only depression compared with usual care.

  34. Editorials

    1. Quality lung cancer screening protects quality of life: No harm, no foul

      Jamie S. Ostroff

      Article first published online: 25 JUL 2014 | DOI: 10.1002/cncr.28835

      This ancillary paper from the NLST dataset examines the impact of undergoing LDCT for early detection of lung cancer on health related quality of life and state anxiety assessed at 1 and 6 months following lung screening. Outcomes are compared by screening results. Overall, the findings provide reassurance that undergoing lung cancer screening in the context of a well-designed screening and follow-up protocol poses little or no psychological harm or quality of life impairment to screening participants.

  35. Original Articles

    1. Discipline

      Quality of Life
      You have full text access to this OnlineOpen article
      Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening Trial

      Ilana F. Gareen, Fenghai Duan, Erin M. Greco, Bradley S. Snyder, Phillip M. Boiselle, Elyse R. Park, Dennis Fryback and Constantine Gatsonis

      Article first published online: 25 JUL 2014 | DOI: 10.1002/cncr.28833

      In a large multi-center lung screening trial, participants receiving a false positive or significant incidental finding screen result experienced no significant difference in health related quality of life or state anxiety at 1 or at 6 months after screening relative to those receiving a negative result.

    2. Epidemiology
      Expected population impacts of discontinued prostate-specific antigen screening

      Roman Gulati, Alex Tsodikov, Ruth Etzioni, Rachel A. Hunter-Merrill, John L. Gore, Angela B. Mariotto and Matthew R. Cooperberg

      Article first published online: 25 JUL 2014 | DOI: 10.1002/cncr.28932

      Recently revised clinical guidelines in the United States recommend against prostate-specific antigen screening. Using 2 models of prostate cancer natural history and survival benefit of screening, the authors report that stopping screening for all men may result in many avoidable cancer deaths, but continued screening for men aged <70 years could prevent a majority of avoidable cancer deaths while dramatically reducing overdiagnoses.

    3. Disease Site

      Head and Neck Disease
      You have full text access to this OnlineOpen article
      A model and nomogram to predict tumor site origin for squamous cell cancer confined to cervical lymph nodes

      Arif N. Ali, Jeffrey M. Switchenko, Sungjin Kim, Jeanne Kowalski, Mark W. El-Deiry and Jonathan J. Beitler

      Article first published online: 24 JUL 2014 | DOI: 10.1002/cncr.28901

      A statistical model has been developed that predicts the most likely head and neck site of origin from a cervical “unknown primary” tumor based on epidemiologic and lymph node data derived from the Surveillance, Epidemiology, and End Results database. This model allows for the statistical localization of the most likely tumor site of origin to aid in high-resolution tissue sampling by surgeons searching for a pathologic site diagnosis or radiation field treatment decisions by radiation oncologists.

    4. Discipline

      Radiation Oncology
      Radiotherapy for benign head and neck paragangliomas: A 45-year experience

      Philip Gilbo, Christopher G. Morris, Robert J. Amdur, John W. Werning, Peter T. Dziegielewski, Jessica Kirwan and William M. Mendenhall

      Article first published online: 24 JUL 2014 | DOI: 10.1002/cncr.28923

      Fractionated radiotherapy for head and neck paragangliomas is a safe and efficacious treatment that is associated with a high probability of cure and a low incidence of morbidity. Observation is suitable for asymptomatic patients who are elderly and infirm and have a limited life expectancy.

  36. Correspondence

  37. Review Articles

    1. MYC-associated and double-hit lymphomas: A review of pathobiology, prognosis, and therapeutic approaches

      Adam M. Petrich, Chadi Nabhan and Sonali M. Smith

      Article first published online: 24 JUL 2014 | DOI: 10.1002/cncr.28899

      The co-presence of MYC and BCL2, termed double hit lymphomas, occurs in up to one-third of diffuse large B-cell lymphomas via immunohistochemistry and has a very poor prognosis. There is limited data on clinical management, but increased awareness of this entity will help define criteria for future clinical trial development.

  38. Original Articles

    1. Discipline

      Clinical Trials
      Effect of total dose and fraction size on survival of patients with locally recurrent nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: A phase 2, single-center, randomized controlled trial

      Yun-ming Tian, Chong Zhao, Ying Guo, Ying Huang, Shao-Min Huang, Xiao-Wu Deng, Cheng-Guang Lin, Tai-xiang Lu and Fei Han

      Article first published online: 23 JUL 2014 | DOI: 10.1002/cncr.28934

      Appropriately decreasing the total dose and increasing fraction size in patients with nasopharyngeal carcinoma being treated with radiotherapy can achieve local control rates similar to those achieved with a higher dose. Furthermore, it can improve overall survival by significantly reducing the incidence of severe late complications including mucosal necrosis and massive hemorrhage.

  39. Review Articles

    1. Complications of pelvic radiation in patients treated for gynecologic malignancies

      Akila N. Viswanathan, Larissa J. Lee, Jairam R. Eswara, Neil S. Horowitz, Panagiotis A. Konstantinopoulos, Kristina L. Mirabeau-Beale, Brent S. Rose, Arvind G. von Keudell and Jennifer Y. Wo

      Article first published online: 23 JUL 2014 | DOI: 10.1002/cncr.28849

      Modern radiotherapy techniques, including highly conformal radiation and image-guided conformal brachytherapy, may reduce the risk of radiation-related side effects. The management of side effects, including surgical and chemotherapeutic implications, is discussed.

    2. Management of patients with HER2-positive metastatic breast cancer: Is there an optimal sequence of HER2-directed approaches?

      Amelia B. Zelnak and Kari B. Wisinski

      Article first published online: 23 JUL 2014 | DOI: 10.1002/cncr.28815

      The successful development of therapies targeting the human epidermal growth factor receptor 2 (HER2) has altered the natural progression of disease among patients with HER2-positive metastatic breast cancer. This review focuses on the HER2-directed agents currently available in clinical practice and the literature regarding the optimal sequencing of these agents.

  40. Editorials

    1. Overtreatment of men with early-stage prostate cancer and limited life expectancy

      Matthew R. Danzig and James M. McKiernan

      Article first published online: 17 JUL 2014 | DOI: 10.1002/cncr.28927

      The accompanying article by Daskivich et al explores with rigorous methodology the issue of the overtreatment of men with early stage prostate cancer and limited life expectancy. Particular attention should be paid to the finding of the predominance of radiotherapy in this group, which should not be considered a benign alternative to surgery given the evidence for long-term morbidity after this treatment.

  41. Original Articles

    1. Disease Site

      Genitourinary Disease
      Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer

      Timothy J. Daskivich, Julie Lai, Andrew W. Dick, Claude M. Setodji, Janet M. Hanley, Mark S. Litwin, Christopher Saigal and on behalf of the Urologic Diseases in America Project

      Article first published online: 17 JUL 2014 | DOI: 10.1002/cncr.28926

      This retrospective study characterizes treatment patterns for early stage prostate cancer according to life expectancy in a population-based cohort of US men. Men aged <80 years at diagnosis who have a life expectancy less than 10 years often receive aggressive treatment (mostly radiation therapy) for low-risk and intermediate-risk prostate cancer.

    2. Hematologic Malignancies
      Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)

      Michael E. Rytting, Deborah A. Thomas, Susan M. O'Brien, Farhad Ravandi-Kashani, Elias J. Jabbour, Anna R. Franklin, Tapan M. Kadia, Naveen Pemmaraju, Naval G. Daver, Alessandra Ferrajoli, Guillermo Garcia-Manero, Marina Y. Konopleva, Jorge E. Cortes, Gautham Borthakur, Rebecca Garris, Maria Cardenas-Turanzas, Kurt Schroeder, Jeffrey L. Jorgensen, Steven M. Kornblau and Hagop M. Kantarjian

      Article first published online: 17 JUL 2014 | DOI: 10.1002/cncr.28930

      Retrospective analysis indicates that pediatric-based therapy for ALL is superior to adult-type therapy. This single institution retrospective comparison shows that the two approaches may yield similar outcomes in this patient population.

    3. Discipline

      Outcomes Research
      Coronary artery disease detected by coronary computed tomography angiography in adult survivors of childhood Hodgkin lymphoma

      Daniel A. Mulrooney, Sara E. Nunnery, Gregory T. Armstrong, Kirsten K. Ness, Deokumar Srivastava, F. Daniel Donovan, Beth A. Kurt, Monika L. Metzger, Matthew J. Krasin, Vijaya Joshi, Jean-Bernard Durand, Leslie L. Robison, Melissa M. Hudson and Scott D. Flamm

      Article first published online: 16 JUL 2014 | DOI: 10.1002/cncr.28925

      In the current study, coronary computed tomography angiography identified a significant percentage of survivors of childhood Hodgkin lymphoma with subclinical coronary artery disease. This noninvasive imaging technique may help clinicians to identify those patients who might benefit from lifestyle and/or medication interventions and those for whom lower levels of monitoring may be appropriate.

  42. Correspondence

    1. Cervical cancer: Is the wall crumbling?

      Laeeq Malik and Alex V. Mejia

      Article first published online: 16 JUL 2014 | DOI: 10.1002/cncr.28916

    2. A brick in the wall

      Angelica Nogueira-Rodrigues and Carlos G. Ferreira

      Article first published online: 16 JUL 2014 | DOI: 10.1002/cncr.28918

  43. Original Articles

    1. Discipline

      Pediatric Oncology
      You have full text access to this OnlineOpen article
      Cancer incidence patterns among children and adolescents in Taiwan from 1995 to 2009: A population-based study

      Giun-Yi Hung, Jiun-Lin Horng, Yu-Sheng Lee, Hsiu-Ju Yen, Chao-Chun Chen and Chih-Ying Lee

      Article first published online: 16 JUL 2014 | DOI: 10.1002/cncr.28903

      The authors examine cancer incidence patterns in children and adolescents based on a national, population-based cancer registry of 12,315 individuals in Taiwan from 1995 to 2009. The high rates of malignant hepatic tumors and germ cell neoplasms in Taiwan suggest variations in background risk factors.

  44. Review Articles

    1. Subtyping of triple-negative breast cancer: Implications for therapy

      Vandana G. Abramson, Brian D. Lehmann, Tarah J. Ballinger and Jennifer A. Pietenpol

      Article first published online: 16 JUL 2014 | DOI: 10.1002/cncr.28914

      Triple-negative breast cancer (TNBC) is an aggressive disease with limited treatment options and no approved targeted therapies. This review outlines the current knowledge about TNBC and strategies being explored to specifically target this disease.

  45. Original Articles

    1. Disease Site

      Gynecologic Oncology
      Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53

      Ngai Na Co, David Iglesias, Joseph Celestino, Suet Y. Kwan, Samuel C. Mok, Rosemarie Schmandt and Karen H. Lu

      Article first published online: 16 JUL 2014 | DOI: 10.1002/cncr.28854

      This is the first report that LKB1 is a transcriptional target of p53, and provides the first evidence that loss of wild-type p53 protein may contribute to the loss of LKB1 in high-grade EEC.

    2. Hepatobiliary Disease
      Risk prediction of hepatocellular carcinoma in patients with cirrhosis: The ADRESS-HCC risk model

      Jennifer A. Flemming, Ju Dong Yang, Eric Vittinghoff, W. Ray Kim and Norah A. Terrault

      Article first published online: 16 JUL 2014 | DOI: 10.1002/cncr.28832

      All patients with cirrhosis are at risk of developing hepatocellular carcinoma (HCC), but this risk is not uniform in a heterogeneous population of patients with cirrhosis. The ADRESS-HCC risk model is a useful clinical tool to estimate the risk of HCC in an individual patient with cirrhosis.

    3. Gastrointestinal Disease
      Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)

      Philip A. Philip, Bryan Goldman, Ramesh K. Ramanathan, Heinz-Josef Lenz, Andrew M. Lowy, Robert P. Whitehead, Takeru Wakatsuki, Syma Iqbal, Rakesh Gaur, Jacqueline K. Benedetti and Charles D. Blanke

      Article first published online: 16 JUL 2014 | DOI: 10.1002/cncr.28744

      Simultaneous targeting of the IGF-1R and EGFR signaling pathways for more ffective downstream inhibition of proliferation and survival did not improve outcomes in patients with metastatic pancreatic adenocarcinoma. Patient selection using biomarkers that would predict pathway inhibition is necessary for future studies using targeted agents.

    4. Head and Neck Disease
      Trends and variations in the use of adjuvant therapy for patients with head and neck cancer

      Michelle M. Chen, Sanziana A. Roman, Wendell G. Yarbrough, Barbara A. Burtness, Julie A. Sosa and Benjamin L. Judson

      Article first published online: 15 JUL 2014 | DOI: 10.1002/cncr.28870

      Approximately one-quarter of patients are not receiving National Comprehensive Cancer Network guideline-directed adjuvant therapy. Patient-level and hospital-level factors are associated with variation in the receipt of adjuvant therapy.

    5. Gastrointestinal Disease
      Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304)

      Cornelia M. Ulrich, Cathryn Rankin, Adetunji T. Toriola, Karen W. Makar, Özge Altug-Teber, Jacqueline K. Benedetti, Rebecca S. Holmes, Stephen R. Smalley, Charles D. Blanke and Heinz-Josef Lenz

      Article first published online: 15 JUL 2014 | DOI: 10.1002/cncr.28830

      There were no statistically significant associations noted between 8 functionally significant polymorphisms in 6 genes (MTHFR [C667T, A1298C], SLC191A [G80A], SHMT1 [C1420T], DHFR [Del19bp], TS 1494del, and TSER) involved in folate metabolism and overall survival, disease-free survival, and toxicity in the overall analyses. Nevertheless, there was a trend toward worse disease-free survival and reduced hematological and gastrointestinal toxicities among patients with variant alleles in MTHFR C677T, SLC19A1 G80A, and TSER, respectively.

    6. Discipline

      Psychosocial Oncology
      Pain experiences among a population-based cohort of current, former, and never regular smokers with lung and colorectal cancer

      Adam Gonzalez, Sandra Japuntich, Nancy L. Keating, Robert Wallace, Yulei He, Joanna M. Streck and Elyse R. Park

      Article first published online: 15 JUL 2014 | DOI: 10.1002/cncr.28893

      This large population-based cohort study examined the relations between smoking and pain experiences among patients with lung and colorectal cancer. Results suggest that lung and colorectal cancer patients who smoke report greater pain experiences.

    7. Radiation Oncology
      Does adjuvant radiotherapy benefit patients with diffuse-type gastric cancer? Results from the Surveillance, Epidemiology, and End Results database

      Alexander M. Stessin, Cristina Sison, Allie Schwartz, John Ng, Clifford K.S. Chao and Baoqing Li

      Article first published online: 15 JUL 2014 | DOI: 10.1002/cncr.28913

      The current Surveillance, Epidemiology, and End Results analysis demonstrated a significant survival benefit for adjuvant radiotherapy among patients with diffuse-type gastric cancer. The standard treatment will likely remain controversial until evidence becomes available from phase 3 randomized trials exclusively for diffuse-type gastric cancer.

    8. Clinical Trials
      FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia

      Preetesh Jain, Hun Ju Lee, Wei Qiao, William Wierda, Ohad Benjamini, Jan Burger, Alessandra Ferrajoli, Zeev Estrov, Hagop Kantarjian, Michael Keating and Susan O'Brien

      Article first published online: 15 JUL 2014 | DOI: 10.1002/cncr.28910

      1) The combination of bevacizumab, an antiangiogenic monoclonal antibody, with chemotherapy has improved outcomes in some solid tumors, but its relevance in leukemia is unclear. 2) We have demonstrated that the addition of bevacizumab to standard FCR chemoimmunotherapy in patients with relapsed chronic lymphocytic leukemia does not improve patient outcomes.


  1. 1 - 100
  2. 101 - 166